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Abstract
Emergence of tumor resistance to an anti-cancer therapy directed against a putative target
raises several questions including: (1) do mutations in the target/pathway confer resistance?
(2) Are these mutations pre-existing? (3) What is the relative fitness of cells with/without the
mutation? We addressed these questions in patients with metastatic colorectal cancer
(mCRC). We conducted an exhaustive review of published data to establish a median dou-
bling time for CRCs and stained a cohort of CRCs to document mitotic indices. We analyzed
published data and our own data to calculate rates of growth (g) and regression (d, decay)
of tumors in patients with CRC correlating these results with the detection of circulating MT-
KRAS DNA. Additionally we estimated mathematically the caloric burden of such tumors
using data on mitotic and apoptotic indices. We conclude outgrowth of cells harboring intrin-
sic or acquired MT-KRAS cannot explain resistance to anti-EGFR (epidermal growth factor
receptor) antibodies. Rates of tumor growth with panitumumab are unaffected by presence/
absence of MT-KRAS. While MT-KRAS cells may be resistant to anti-EGFR antibodies,
WT-KRAS cells also rapidly bypass this blockade suggesting inherent resistance mecha-
nisms are responsible and a neutral evolution model is most appropriate. Using the above
clinical data on tumor doubling times and mitotic and apoptotic indices we estimated the
caloric intake required to support tumor growth and suggest it may explain in part cancer-
associated cachexia.
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Introduction
Intrinsic and acquired drug resistance, long recognized as impediments to the therapy of can-
cer have also emerged as problems with “targeted agents”. Described initially as acquired
mutations in BCR-ABL, the target of imatinib, it was hoped it would be more straightforward
than with “traditional cytotoxic agents” [1]. However, its pleiotropic nature is now well recog-
nized and in many cases our understanding is wanting [2].
Mechanisms of resistance to “targeted therapies” include mutations in the drug target [3,4],
reduced drug accumulation [5], and cellular adaptations to target engagement [6,7] among
others. In the case of cetuximab and panitumumab, antibodies targeting the epidermal growth
factor receptor (EGFR), prospective and retrospective analyses in patients with colorectal can-
cer (CRC) established the importance of KRAS mutations on sensitivity to these agents [8–10].
While ongoing investigations suggest some KRAS mutations may have less or no impact on
anti-EGFR antibody sensitivity it is generally accepted patients whose tumors harbor mutant
KRAS are less likely to benefit from anti-EGFR antibodies [11,12]. This clinical data has con-
firmed what was predicted nearly two decades ago–KRAS mutations constitutively activate the
pathway through which the EGFR signals, making cells harboring activating mutations refrac-
tory to therapies that block the pathway proximal to KRAS [13].
While identification of mutant KRAS as a mechanism of intrinsic resistance to anti-EGFR
antibodies has “personalized” this therapy and begun identifying those most likely to have bet-
ter outcomes, the clinical benefit remains limited—a gain of a few months in survival—with
hope better selection will bring further improvements [14–16]. The possibility an acquired
KRAS mutation or selection of a clone harboring a KRAS mutation could explain acquired
resistance to cetuximab and panitumumab has appeal but is theoretically unlikely. Especially
in second line therapy of CRC, with median times to progression of a only a few months, it is
unlikely a single cell acquiring a KRAS mutation or even a pre-existing clone could become a
substantive portion of a tumor that even at 2 cm in diameter has approximately 8 billion cells.
Hoping to “personalize” cancer therapy and enhance our understanding of cancer biology,
several groups have developed assays to quantitate circulating tumor DNA. One such effort
attempted to quantitate circulating tumor DNA harboring KRAS mutations in patients with
refractory CRC receiving panitumumab [17]. In a minority of cases, “acquired mutations”
detected in serum were implicated in panitumumab resistance. This rich data set offers an
opportunity to examine the likelihood KRAS mutations confer acquired resistance to an anti-
EGFR antibody and provided a platform to examine variables affecting tumor-doubling times.
We compared the growth kinetics of tumors deemed refractory to panitumumab with those of
tumors in an independent cohort treated in second line. We conclude acquired KRAS muta-
tions are an improbable mechanism of panitumumab tolerance. We also describe a mathemat-
ical analysis critically assessing tumor-doubling times, challenge some previous assumptions
and provide insight into the caloric burden of tumors.
Results
An exhaustive review of published data shown in Table 1, allowed us establish a median dou-
bling time of six months for CRCs. Using radiographic measurements, the doubling times of
CRCs in patients range from 2.9 to 31.0 months (median 6.8 months). Consistent with this, we
found experimentally in thirteen CRCs as shown in Fig 1 and Table 2, a median of only eight
mitosis/HPF and 0.3% of all cells in mitosis. This was further corroborated by phosphohistone
staining, a marker of mitosis that stained very few cells in these CRCs. Importantly in these
thirteen samples 40–70% of cells stained positive for MIB-1/Ki-67. The monoclonal antibody,
MIB-1, was developed using recombinant portions of the Ki-67 nuclear antigen as
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immunogen. As such MIB-1 recognizes Ki-67, which is associated with cell proliferation and
is found throughout the cell cycle (G1, S, G2, and M phases) but not in resting (G0) cells. The
MIB-1 / Ki-67 proliferation index is defined as the percent of immunoreactive tumor cells in
the evaluated area. The high MIB-1 indices relative to the very low percent of malignant cells
in mitosis as summarized in Table 2 underscores the fact MIB-1/Ki-67 staining, is a “marker
of proliferation” and not a surrogate for cell division [18].
Next we analyzed published data on 24 patients with CRC treated in second line with pani-
tumumab-containing regimens [17] comparing this data with that in an additional 22 patients
with CRC treated in second line with similar oxaliplatin or irinotecan-containing regimens
with/without anti-EGFR antibodies. The published and our own clinical data allowed us to cal-
culate rates of growth (g) and regression (d, decay) of tumors in these patients with a method-
ology validated using measurements of tumor quantity from >6000 patients with diverse
cancers treated with various chemotherapeutics [19–22]. These analyses have demonstrated
the quantity of tumor measured is the sum of the tumor quantity that is regressing and is sensi-
tive to therapy plus the tumor quantity that is relatively resistant and growing. Published data
on 24 patients with CRC whose tumors were initially KRAS-WT, reported circulating MT-
KRAS DNA as “newly detected” in nine treated in second line with panitumumab plus chemo-
therapy [15]. Using the actual published data of serial tumor quantities [17] we calculated the
growth (g) and regression (d) rates for the individual tumors. We did this by fitting the data, as
shown in Fig 2, and readily calculating the growth rate (g) of tumors in the nine patients with
newly detected circulating MT-KRAS DNA (Fig 2A). As shown in Fig 3, we determined the
growth rate of tumors in the nine patients with newly detected circulating MT-KRAS DNA to
be 0.0019 days-1. This value was statistically indistinguishable [p = .244] from the growth rate
of 0.0021 days-1 calculated for tumors in the fifteen patients without detectable circulating
MT-KRAS DNA (Fig 2B). Importantly, we further compared the growth rates of these tumors
to those of tumors in patients receiving conventional second line therapies both with/without
Table 1. Doubling times of colorectal carcinomas.
Author (year) Clinical Presentation Time (months)





Kim et al (2012) Pulmonary metastasis 5.3
Sadahiro (2005) Pulmonary metastasis 2.1
Umetani et al (2000) Non pedunculated colorectal carcinomas 6.8
Matsui et al (2000) Colorectal carcinoma mucosa 31
Colorectal carcinoma submucosa 25
Colorectal carcinoma muscularis propria 13
Colorectal carcinoma serosa 13
Finlay et al (1988) Overt liver metastasis 5.1
Occult liver metastasis 2.9
Tada et al. (1984) Colon Carcinomas 3 to 34
Adenomatous polypus 4.8 to 13.2
Bolin et al. (1983) Colon and rectal carcinoma 4.3
Range 2.9–31
Median (using lowest values for two reports with a range) 6.8
https://doi.org/10.1371/journal.pone.0175484.t001
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Fig 1. Example of a case of CRC [40X magnification]. Stains include hematoxylin and eosin (H&E), Ki-67
(MIB-1) and phosphohistone immunohistochemistry. The Ki-67 protein is associated with cell proliferation and
expression can be detected during all active phases of the cell cycle (G1, S, G2, and mitosis), but is absent in
resting cells (G0)18. The MIB-1 antibody was used to determine the Ki-67 labeling index. Phospho-histone H3(Ser
10) is expressed in the nuclei of cells during M-phase (mitosis) allowing one to use phosphohistone staining as a
means to identify cells in mitosis. H&E stain (A, x400) including atypical mitotic figures (B, x400). MIB-1/Ki-67
stain demonstrating a high proliferation index (C, x40). Phosphohistone stain demonstrating cells in mitosis [D,
x400].
https://doi.org/10.1371/journal.pone.0175484.g001
Table 2. Tabulation of mitosis in colorectal cancers.
CRC Sample Mitoses per 10 HPF Percent of malignant cells in mitosis Ki-67 / MIB-1 proliferation index
1 8 0.3% 50 − 60%
2 23 0.7% 60%
3 4 0.3% 50 − 60%
4 3 0.1% 30 − 40%
5 6 0.3% 60 − 70%
6 20 0.9% 60 − 70%
7 5 0.2% 50 − 60%
8 6 0.2% 40 − 50%
9 30 0.7% 70%
10 9 0.3% 60 − 70%
11 9 0.3% 50 − 60%
12 5 0.2% 40 − 50%
13 12 0.3% 60 − 70%
Median 8 0.3% 55%
Range 3–30 0.1%—0.9% 30–70%
https://doi.org/10.1371/journal.pone.0175484.t002
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Fig 2. Evolution of tumors in patients is shown as graphs of RECIST measurements. A: Nine patients with
detectable MT KRAS DNA in serum. B: Nine patients without detectable MT KRAS DNA in serum. As can be seen the
kinetics of tumor regression and growth of these tumors is indistinguishable. Detection of a mutant KRAS DNA is
serum, interpreted as evidence of “acquiring” this genetic alteration, does not impact the growth of the tumor. The blue
lines are the lines drawn by the model and this demonstrates how well the theoretical (blue line) fit the actual (red
symbols). The fit of the actual data to the theoretical had p values less than 0.05 in all cases, and in most much less
than that.
https://doi.org/10.1371/journal.pone.0175484.g002
Fig 3. Comparison of growth rate (g) using tumor measurements from Diaz et al [17] and from an
independent CRC tumor data set of patients treated in second line with conventional chemotherapy.
Top 2 panels: The growth (g, p = 0.244) and regression (d, p = 0.858) rates of tumors treated with panitumumab
in which mutant KRAS DNA could be detected in serum (MT) do not differ from those of tumors without
detectable mutant KRAS DNA in serum (WT). Lower 2 panels: Compared to tumors independently treated in
second line with conventional chemotherapy the growth rates (g) of the panitumumab-treated tumors is similar
for both the subgroup with detectable circulating mutant KRAS DNA (MT) in serum and those without detectable
mutant KRAS DNA in serum (WT).
https://doi.org/10.1371/journal.pone.0175484.g003
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anti-EGFR antibodies. The average growth rate of these twenty-two tumors, 0.002 days-1, was
statistically indistinguishable from the growth rate calculated for the tumors treated with pani-
tumumab—p values of .306 and .769 for comparisons with those with/without circulating MT-
KRAS DNA, respectively. Furthermore using published serial CEA values in a subset of the
patients treated with panitumumab [17], similar results were obtained with estimated growth
rates of 0.0031 days-1 and 0.0021 days-1 in tumors with/without circulating MT-KRAS DNA,
respectively [p = .1265]. We also found statistically indistinguishable (p = .858) rates of tumor
regression for tumors with/without circulating MT-KRAS DNA, 0.0117 days-1 and 0.0114
days-1, respectively (Fig 3). Finally, using a mathematical analysis (S1 File) we show that the
KRAS mutant and KRAS wild type populations evolve together with little evidence of competi-
tion and with the same growth rates.
Although the foregoing established that selection of a mutant KRAS clone cannot explain
acquired resistance to an anti-EGFR antibody the analysis brought into focus how such a clone
could emerge, specifically how fast a tumor has to divide and what can be sustained. Because
these calculations are relevant to other situations where clonal overgrowth might be consid-
ered, we sought to determine mathematically using our own and published data what would
occur and the caloric requirements needed to sustain tumor growth. In this regard, if one
knows the mitotic index, the average times for mitosis and apoptosis, and the actual tumor
doubling times measured clinically, an apoptotic rate can be inferred allowing one to estimate
the tumor quantity lost due to cell death as tumors grow (S1 File, S1–S3 Data)
Tumor doubling times measured clinically using radiologic imaging or serum markers—a
value we will term the clinical tumor doubling time (CTDT)–are much longer than one would
estimate using the mitotic index obtained histologically (Table 2). The large number of cells
that die concurrently explains the difference. Using the measured mitotic index we can calcu-
late first what would be the tumor doubling time in the absence of apoptosis, a value we will
call the minimal doubling time (MDT). We distinguish the MDT from the actual CTDT that
as will be seen is always a larger value because while some tumor cells divide, others die. Using
our measured mitotic index of 0.3%, and a 2-hour value for the duration of mitosis or the time
during which cells are counted as “mitotic” and contribute to the mitotic index [23,24], we
obtain 19.8 days as the MDT (S1 File). This is to be contrasted with a value of four days used
by others [17,25], a value more appropriate for mouse colonic crypts. For the MDT to be four
days (in the absence of apoptosis) the mitotic index has to be higher (1.6%) than the one we
observed (0.3%). But as we have noted, apoptosis occurs concurrently with mitosis, and one
can calculate the apoptotic index that together with a given mitotic index will achieve actual
CTDTs (S1 File, S1–S3 Data). Estimates of the time spent in apoptosis [26–28] allow one to
estimate an apoptotic index, the percent of cells in apoptosis at any time. Thus, for example,
with a CTDT of 60 days, a mitotic index of 0.3%, 2-hours spent in mitosis, and 2-hours as the
time spent in apoptosis we obtain an apoptotic index of 0.19%. By comparison if one assumes
a MDT of four days [17,23] the apoptotic index must be 1.2% (S1 File, S1–S3 Data).
Given the calculations above that establish the apoptotic index one can estimate the ratio of
cells that die to new cells arising from mitosis. We will use the term ϕ for the ratio of the num-
ber of cells that must die as the quantity of tumor doubles (the CTDT). Note that in this analy-
sis the number of cell divisions needed to double the quantity of tumor is independent of
tumor size. Using our mitotic index of 0.3% we determine that ϕ is2. By comparison if one
assumes the MDT to be 4 days, ϕ increases to 15. In the first example with ϕ2, as a tumor
doubles from 0.5 kg to 1kg, one kg of tumor is lost (dies) as 0.5 kg of new “viable” tumor is
added. With ϕ15 as the tumor doubles from 0.5 kg to 1 kg, 7.5 kilograms of tumor are lost
(die) as 0.5 kg of new “viable” tumor is added. That is to say, 8 kg of tumor are produced and
only 0.5 kg survive, while the other 7.5 kg die. Given that it takes7,700 kcal to create a kg of
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tissue with a ϕ2 an additional11,550 kcal [7,700 x 1.5] calories will need to be consumed
during the CTDT– 60-days for CRC—to produce the viable and dead tumor, an average of
200 extra kcal/day. Most of these calories would be required towards the end of the 60-day
CTDT, because the number of dying cells scales as the power of number of days (Supporting
Information). In the case of a MDT of 4 days the number of additional calories needed would
be61,600 or1,027 kcal per day. In Fig 4, we depict the additional calories a patient must
consume to support tumor growth with estimates provided in Fig 4C for the number of calo-
ries needed in the case of different mitotic indices, assuming at the time of death the quantity
of tumor has reached 2 kg, a quantity that would take 11 doublings to reach starting from 1
gram of tumor. In Supporting Information we show that the total number of dead cells is Δ =
N0ϕ(2J+1–1), where the constant factor ϕ relates the initial number of cells and the number of
cells that die during doubling of the tumor. The number of cells that die after 11 doublings is Δ
= 4095N0ϕ. Starting with one gram of tumor, which has approximately a billion cells, we see
that the total mass of tumor that dies as the cancer grows is Δ = 4.095ϕ kg. The factor ϕ is a
very important parameter reflecting the tumor biology and prognosis in every patient. In Sup-
porting Information we calculate ϕ for different mitotic rates. In Fig 5A, we plot the viable
tumor mass depicting a tumor that does not decrease at all during progression, and one where
intermittent treatments lead to transient decreases in tumor size. In the latter as resistance
emerges the tumor grows. Note that the calculations in Fig 4 do not involve any decrease dur-
ing progression and thus provides estimates for the minimum amount of new tumor formed
and the minimum caloric requirements. Fig 5B depicts the quantity of tumor that undergoes
apoptosis during this period based on the two different estimates of the MDT (our estimate of
19.8 and the value of 4 days claimed by others).
Fig 4. Estimates (A) the cumulative number of additional kilocalories and (B) the number of additional
kilocalories per day required by a tumor for each successive 60-day doubling period required due to the
tumor. The estimates are for two different mitotic and apoptotic indexes. The doubling time is 60 days and the
tumor mass progresses through 11 doublings. The estimates include the number of calories to produce both
the cell that survive, as well as those that undergoes apoptosis. (C) Estimates for the number of calories
needed to support a tumor.
https://doi.org/10.1371/journal.pone.0175484.g004
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While these estimates capture the growth phase of tumors, most patients are under treat-
ment during disease progression and for at least part of the treatment period the tumor mass
decreases in time as depicted in Fig 5A. We show this to underscore that our estimates do not
include the receding phases of the tumors and thus underestimate the calories needed during
actual treatment.
Discussion
We embarked on this analysis to better understand resistance to a targeted therapy. Although
acquired mutations have been identified in patients receiving BCR-ABL and BRAF inhibitors,
such mutations have not been described with VEGF or mTOR inhibitors amongst others, sug-
gesting mechanisms other than mutations in the target or its pathway might be equally if not
more important. Given the detailed understanding of the EGFR pathway and clinical data
demonstrating a lack of efficacy for EGFR blockade in cells harboring KRAS mutations, pub-
lished data offered a valuable model to explore the importance of mechanisms of resistance
[17]. From our analysis we conclude that as regards KRAS in metastatic colorectal cancer
(mCRC) treated with an anti-EGFR antibody a neutral evolution model and not KRAS muta-
tions provides a greater understanding of the clinical outcome.
The neutral theory of molecular evolution posits that most genetic variation results from ran-
dom mutations and genetic drift and not from natural selection. Because such neutral muta-
tions do not affect the ability to survive or reproduce, the fitness of any given cell in a
population is unaffected by the version of the gene a cell harbors. Neither the published data
nor our data is sufficient to conclude acquired resistance to the anti-EGFR antibody panitu-
mumab is due to the emergence of cells harboring mutant KRAS. While circulating MT-KRAS
was detected in the serum of some patients, given known tumor heterogeneity, it would not be
surprising that the occurrence and expression of mutant KRAS in some tumors is heteroge-
neous. This would lead to detection of circulating mutant KRAS as tumor burden increased
and all cells increased in number including those harboring wild-type or mutant-KRAS. In this
Fig 5. (A) Progression of tumor quantity from 1 gram to 2 kilograms with a doubling time of 60 days. The blue
curve depicts a tumor that does not decrease at all during progression, while the red curve depicts an example
where intermittent treatments lead to transient decreases in tumor size. Resistance then emerges and the tumor
again beings to grow. Thus the blue model that we use provides estimates for the minimum amount of new
tumor formed and the minimum caloric requirements. (B) Total amount of tumor that undergoes apoptosis as
the net tumor quantity increases from 1 gram to 2 kilograms for two different mitotic (μ) and apoptotic (α)
indexes. The doubling time is 60-days and the tumor mass progresses through 11 doublings.
https://doi.org/10.1371/journal.pone.0175484.g005
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case an assay detecting circulating mutant KRAS simply detects more tumor; it does not
explain drug tolerance.
Furthermore, in patients with MT-KRAS in the serum, the growth rate remained constant
even as circulating MT-KRAS was initially detected or appeared to increase, suggesting (1) the
detection or increase in mutant KRAS templates was inconsequential, and (2) not only the
growth rate of the entire tumor was constant but cells harboring MT-KRAS had no impact on
the tumor’s growth rate nor were likely growing faster. As regards the latter, one would expect
cells that might be resistant to grow or accumulate faster and in turn accelerate the rate of
tumor growth. Indeed with a stated conversion factor of 44 million KRAS-mutant cells for
every mutant KRAS template/ml [17], the estimated MT-KRAS tumor burden ranged from
0.13 grams to 21 grams, with 7/9 patients with circulating MT-KRAS having <5 grams of
tumor harboring a KRAS mutation. These values, easily estimated using published data [17],
represent only a very small fraction of the tumor burden and could not meaningfully contrib-
ute to tumor growth in these patients with refractory CRCs who likely have several hundred
grams or more of tumor. Such small quantities may also explain the fluctuations in circulating
mutant KRAS seen with the data. Thus, one can confidently conclude mutant KRAS did not
confer a growth advantage and leads us to conclude that as regards agents targeting the EGFR
a neutral evolution model best explains the data.
A possible reason for the neutral evolution of different cell populations is that by the time a
patient presents with advanced disease, the various cell populations in a cancer have under-
gone a prolonged selection and have similar growth rates. As mutations are only important if
they confer an advantage—in this case the ability to grow better during panitumumab therapy
—one can further conclude detection of such mutations was inconsequential. However, the
data is inconclusive whether MT-KRAS cells are/are not resistant to panitumumab and
whether they co-exist with other resistant clones.
As we conducted these analyses we also realized very little attention has been given to the
simultaneous occurrence of mitosis and apoptosis in tumors. Previous studies that have
reported “b0.25 for colorectal cancer cells”, corresponding to one cell division every 4 days”
[17,23] are difficult to reconcile with the literature summarized in Table 1 and with our own
estimate of tumor-doubling times of130 days using linear RECIST dimensions, and assum-
ing the tumors approximated spheres. In this case a 27% increase in the linear dimension (1.27
compared to original) would double tumor volume with an estimated tumor-doubling time of
130 days:
Doubling time ¼ ½ln 1:27=Tumor growth rateconstant ¼ ½0:239=0:0019 ¼ 126 days
A similar value was estimated using CEA as the measure of tumor quantity or volume.
Additionally we would note that one cell division every four days means a patient presenting
with a single 2 cm tumor—a minimal amount for a patient with metastatic CRC—would have
more than 2 kilograms of tumor one month later and more than 500 kilograms at two months
—unless more than 99% of the cells underwent apoptosis, a highly unlikely proposition con-
firmed by examining any mCRC histologically and finding, as shown in Fig 1, primarily viable
not necrotic or apoptotic cells therein.
Finally, we realized the data provided us the opportunity to address the extent to which apo-
ptosis occurs and provide some estimates of caloric consumption needed to support tumor
growth. Cancer cachexia (CC) is characterized by energy imbalance, due to increased energy
expenditure and/or reduced energy intake reduced [29]. Although poor appetite with dimin-
ished energy intake plays an important role in CC, this alone cannot account for weight loss in
cancer patients [30], a thesis supported by the fact that intensive nutritional support such as
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total parenteral nutrition fails to reverse CC [31]. This suggests increased energy expenditure
and metabolic derangements are likely important features of CC. A number of studies have
demonstrated resting energy expenditure (REE) is increased in various cancers including lung,
and gastrointestinal cancers [32–35]. Patients with stage IV cancer have higher REE compared
to those with lower stage disease [35], while patients with non-small cell lung cancer with ele-
vated REE who undergo curative resection have a decrease in REE [36]. Finally in patients
with mCRC similar to those in this study, other investigators using computed tomography
imaging data and a mathematical model concluded increases in REE may contribute substan-
tially to CC-associated weight loss. Specifically they noted that increases in the mass and pro-
portion of high metabolic rate tissues, including liver and tumor, led to a cumulative
incremental REE of 17,700 kcal during the last 3 months of life, estimates similar to ours and
not consistent with 4-day doubling times [37]. We would note that in principle it might be
possible to address this issue in a trial, however it might be impractical given that the patient’s
weight is a complex function of their metabolism, type of treatment administered and the
tumor’s response to the treatment, supportive measures and other factors.
The low mitotic indices we observed indicate only a minority of cells are “in cycle” at any
one time. But with doubling times of 60 days clinically—values in the low range of reported—a
substantial amount of cell death occurs and indeed more tumor dies than is newly generated
suggesting tumor growth is relatively inefficient. Using our most conservative estimates it
becomes apparent that as cancers grow an increasing number of calories are required to sup-
port tumor growth, amounts that can exceed several hundred calories per day. In a cancer
patient with a reduced appetite this could contribute to the problem of CC. As to whether
some of the caloric requirements be satisfied by autophagy, we think this unlikely [38–40]. As
our understanding of this lysosomal degradation process evolves, it is increasingly clear its
principal functions are not to provide calories but rather to adapt to stress, maintain cellular
homeostasis, and promote survival. Furthermore, it would not be energy efficient or an
energy-free source of calories, and would likely only satisfy a small fraction of the patient’s
needs.
In summary, we conclude KRAS mutations are insignificant as a mechanism of resistance
to EGFR blockade. A neutral evolution model and not KRAS mutations provides a greater
understanding of the clinical outcome. Whether novel strategies designed to enhance the effi-
cacy of EGFR blockade will be effective remains to be determined [41]. We also find that
despite low mitotic indices and relatively “long” tumor doubling times tumors impose a sub-
stantial caloric burden on patients.
Materials and methods
Data
The data used had either been previously published and available in the public domain or was
obtained from patients enrolled in studies or receiving standard of care therapy at Gregorio
Marañon University Hospital. The studies on which patients were enrolled had the approval of
the Gregorio Marañon University Hospital IRB and the Agencia Española del Medicamento
and informed written consent was obtained from all patients. As we analyzed data regarding
the effect of various drugs but did not change a patient’s treatment (retrospective / observa-
tional study) the analysis was exempt by the Agencia Española del Medicamento.
Mathematical analysis
Our regression-growth equation sees the change in tumor quantity during therapy resulting
from 2 independent component processes (both following first order kinetics): an exponential
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decay/regression, d, and an exponential growth/regrowth of the tumor, g. Eq 1 is:
f ðtÞ ¼ expð  d  tÞ þ expðg  tÞ   1 ð1Þ
Where the tumor quantity (f, sum of LDs) for a given time t (days), is a non-linear function of
d (decay), g (growth) and time (t). All tumor quantities are divided by 1, the assigned tumor
quantity at time zero; exp is the base of the natural logarithms. For data showing a continuous
decrease from start of treatment, g is eliminated:
f ðtÞ ¼ expð  d  tÞ ð2Þ
Similarly, when tumor measurements show a continuous increase, d is eliminated:
f ðtÞ ¼ expðg  tÞ ð3Þ
Data analysis
We modeled each data set. Parameters were estimated with associated Student t and P values
and predicted values were obtained using SAS software and the procedure NLIN, a non-linear
regression model.
Immunohistochemistry
Cases of metastatic colorectal cancer were selected and pathology reviewed on paraffin-embed-
ded, hematoxylin and eosin stained sections, with special attention to mitotic activity and pro-
liferation index. Immunohistochemistry for Ki-67 (Dako, Product no. M7240, dilution 1:200)
was performed using a Ventana Benchmark autostainer (Ventana Medical Systems, Tucson,
AZ). Phosphohistone immunostains were performed using Phospho-Histone H3 (Ser28) Anti-
body from Cell Signaling (Danvers, MA). Mitotic index (MI) represents the number of mitotic
figures per 10 high power fields (hpf); the number of mitotic figures was counted in a larger
area of the tumor (total of 10 hpf) and does not take into account the tumor cell density. The
percent mitoses were calculated as the number of mitotic figures per 100 cells (estimated using
an ocular grid). As in many cancers, the MIB-1/Ki-67 proliferation index varied in different
areas of the tumor. Tumor areas with the highest density of positively staining nuclei were
identified on low power scanning and these areas were used for estimating percent positive
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